The FDA has expanded the approval for enzalutamide (Xtandi) to include the treatment of men with chemotherapy-naive metastatic castration-resistant prostate cancer.
Silas Inman, OncLive
Advertisement
Articles by Silas Inman, OncLive
Pertuzumab (Perjeta) in combination with trastuzumab and chemotherapy has become the first FDA-approved neoadjuvant treatment for patients with breast cancer.
Advertisement
Latest Updated Articles
FDA Approves Neoadjuvant Pertuzumab RegimenOctober 1st 2013
Advertisement
Advertisement
Trending on Pharmacy Times
1
Updated 2025-2026 COVID-19 Vaccine Nearly Halved ED Visits, Hospitalizations in CDC-Funded Study
2
The Biosimilar Conversation Nobody Is Having at the Pharmacy Counter: Why Adoption Is Still Struggling and What We Can Do About It
3
Medicare Is Finally Covering GLP-1s for Weight Loss: What the Bridge Program Means for Your Practice
4
FDA Narrows Compounding Rules for GLP-1s: How Pharmacists Should Respond
5